{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:36:42Z","timestamp":1783741002584,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"DOI":"10.7759\/cureus.87544","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:04:04Z","timestamp":1752073444000},"source":"Crossref","is-referenced-by-count":1,"title":["A Mycophenolic Acid Concentration-Time Curve (0-12 Hours) to Maintain Remission Without Recurrent Infection in C1q Nephropathy: A Case Report"],"prefix":"10.7759","author":[{"given":"Marika","family":"Ishii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Maru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007080929","article-title":"Pathology, clinical presentations, and outcomes of C1q nephropathy","volume":"19","author":"Vizjak A","year":"2008","unstructured":"Vizjak A, Ferluga D, Rozic M, et al.. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol. 2008, 19:2237-44. 10.1681\/ASN.2007080929","journal-title":"J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(85)80150-5","article-title":"C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome","volume":"6","author":"Jennette JC","year":"1985","unstructured":"Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis. 1985, 6:103-10. 10.1016\/s0272-6386(85)80150-5","journal-title":"Am J Kidney Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-008-1058-9","article-title":"C1q nephropathy and minimal change nephrotic syndrome","volume":"24","author":"Wong CS","year":"2009","unstructured":"Wong CS, Fink CA, Baechle J, Harris AA, Staples AO, Brandt JR. C1q nephropathy and minimal change nephrotic syndrome. Pediatr Nephrol. 2009, 24:761-7. 10.1007\/s00467-008-1058-9","journal-title":"Pediatr Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.01151.x","article-title":"Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity","volume":"6","author":"Borrows R","year":"2006","unstructured":"Borrows R, Chusney G, Loucaidou M, et al.. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant. 2006, 6:121-8. 10.1111\/j.1600-6143.2005.01151.x","journal-title":"Am J Transplant"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/0-387-32957-9_12","article-title":"BK virus and immunosuppressive agents","volume":"577","author":"Agha I","year":"2006","unstructured":"Agha I, Brennan DC. BK virus and immunosuppressive agents. Adv Exp Med Biol. 2006, 577:174-84. 10.1007\/0-387-32957-9_12","journal-title":"Adv Exp Med Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020439","article-title":"Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients","volume":"347","author":"Hirsch HH","year":"2002","unstructured":"Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002, 347:488-96. 10.1056\/NEJMoa020439","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2011.01.001","article-title":"Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation","volume":"25","author":"T\u00f6nshoff B","year":"2011","unstructured":"T\u00f6nshoff B, David-Neto E, Ettenger R, et al.. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev (Orlando). 2011, 25:78-89. 10.1016\/j.trre.2011.01.001","journal-title":"Transplant Rev (Orlando)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation","volume":"5","author":"Kuypers DR","year":"2010","unstructured":"Kuypers DR, Le Meur Y, Cantarovich M, et al.. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010, 5:341-58. 10.2215\/CJN.07111009","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0009-9236(99)70012-3","article-title":"The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients","volume":"66","author":"Johnson AG","year":"1999","unstructured":"Johnson AG, Rigby RJ, Taylor PJ, et al.. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther. 1999, 66:492-500. 10.1016\/s0009-9236(99)70012-3","journal-title":"Clin Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0009-9120(00)00196-x","article-title":"A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients","volume":"34","author":"Pillans PI","year":"2001","unstructured":"Pillans PI, Rigby RJ, Kubler P, et al.. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients. Clin Biochem. 2001, 34:77-81. 10.1016\/s0009-9120(00)00196-x","journal-title":"Clin Biochem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin BH","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, et al.. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021, 100:S1-S276. 10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(81)80760-3","article-title":"The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children","volume":"98","author":"The International Study of Kidney Disease in Children (ISKDC)","year":"1981","unstructured":"The International Study of Kidney Disease in Children (ISKDC). The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr. 1981, 98:561-4. 10.1016\/s0022-3476(81)80760-3","journal-title":"J Pediatr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-009-1429-x","article-title":"C1q nephropathy in the pediatric population: pathology and pathogenesis","volume":"25","author":"Wenderfer SE","year":"2010","unstructured":"Wenderfer SE, Swinford RD, Braun MC. C1q nephropathy in the pediatric population: pathology and pathogenesis. Pediatr Nephrol. 2010, 25:1385-96. 10.1007\/s00467-009-1429-x","journal-title":"Pediatr Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02701-5","article-title":"Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study","volume":"75","author":"Sobiak J","year":"2019","unstructured":"Sobiak J, Resztak M, Pawi\u0144ski T, \u017bero P, Ostalska-Nowicka D, Zachwieja J, Chrzanowska M. Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study. Eur J Clin Pharmacol. 2019, 75:1249-59. 10.1007\/s00228-019-02701-5","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5812\/numonthly.8308","article-title":"Diverse clinical and histology presentation in c1q nephropathy","volume":"5","author":"Malleshappa P","year":"2013","unstructured":"Malleshappa P, Vankalakunti M. Diverse clinical and histology presentation in c1q nephropathy. Nephrourol Mon. 2013, 5:787-91. 10.5812\/numonthly.8308","journal-title":"Nephrourol Mon"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr572","article-title":"Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome","volume":"27","author":"Gellermann J","year":"2012","unstructured":"Gellermann J, Ehrich JH, Querfeld U. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 2012, 27:1970-8. 10.1093\/ndt\/gfr572","journal-title":"Nephrol Dial Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31817c6447","article-title":"Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication","volume":"86","author":"Dadhania D","year":"2008","unstructured":"Dadhania D, Snopkowski C, Ding R, et al.. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation. 2008, 86:521-8. 10.1097\/TP.0b013e31817c6447","journal-title":"Transplantation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.06.017","article-title":"Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters","volume":"77","author":"Sobiak J","year":"2015","unstructured":"Sobiak J, Resztak M, Ostalska-Nowicka D, Zachwieja J, G\u0105siorowska K, Piechanowska W, Chrzanowska M. Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. Eur J Pharm Sci. 2015, 77:189-96. 10.1016\/j.ejps.2015.06.017","journal-title":"Eur J Pharm Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/374896-a-mycophenolic-acid-concentration-time-curve-0-12-hours-to-maintain-remission-without-recurrent-infection-in-c1q-nephropathy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T15:04:05Z","timestamp":1752073445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/374896-a-mycophenolic-acid-concentration-time-curve-0-12-hours-to-maintain-remission-without-recurrent-infection-in-c1q-nephropathy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.87544","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}